Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Márta Marschalkó

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Bőrgyógyászati és Venerológiai Szemle

2019

English

Meningovascular Neurosyphilis as the Cause of Ischemic Cerebrovascular Disease in a Young Man

Orvosi Hetilap

Medicine

2011

English

Related publications

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

English

Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Vestnik dermatologii i venerologii

2019

English

Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports

Immunopathology, Allergology, Infectology

2018

English

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Hematological Oncology

English

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Journal of the National Comprehensive Cancer Network : JNCCN

Medicine

Oncology

2014

English

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

OncoTargets and Therapy

Oncology

Pharmacology

2016

English

Prognostic Factors in Patients With Relapsed or Refractory Systemic Anaplastic Large T-Cell Lymphoma (Alcl) Receiving Brentuximab Vedotin and Outcome After Treatment Failure.

Hematological Oncology

English

Treatment of Cutaneous T-Cell Lymphoma: An Update

Journal of the American Osteopathic Association, The

English

Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)

Hematological Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Márta Marschalkó

Our First Experiences With Brentuximab Vedotin in the Treatment of Cutaneous T-Cell Lymphoma

Meningovascular Neurosyphilis as the Cause of Ischemic Cerebrovascular Disease in a Young Man

Related publications

FDA Approval Summary: Brentuximab Vedotin in First‐Line Treatment of Peripheral T‐Cell Lymphoma

Potentials of Brentuximab Vedotin in the Treatment of Relapse/Refractory Cutaneous T-Cell Lymphomas: Literature Review and Authors’ Observation

Successful Outcomes of Brentuximab Vedotin Therapy in Recurrent/Refractory Cutaneous T-Cell Lymphomas: Two Case Reports

First Salvage Treatment With Bendamustine and Brentuximab Vedotin in Hodgkin Lymphoma: A Phase 2 Study of Fil Onlus

Brentuximab Vedotin in Patients With Relapsed HIV-Related Lymphoma

Patient-Reported Outcomes of Brentuximab Vedotin in Hodgkin Lymphoma and Anaplastic Large-Cell Lymphoma

Prognostic Factors in Patients With Relapsed or Refractory Systemic Anaplastic Large T-Cell Lymphoma (Alcl) Receiving Brentuximab Vedotin and Outcome After Treatment Failure.

Treatment of Cutaneous T-Cell Lymphoma: An Update

Final Data From the Phase 3 Alcanza Study: Brentuximab Vedotin (Bv) vs Physician's Choice (Pc) in Patients (Pts) With Cd30-Positive (Cd30+) Cutaneous T-Cell Lymphoma (Ctcl)